Novus Therapeutics, Inc. (NVUS) Can’t Be More Hot. Just Reaches 52-Week High

June 4, 2018 - By Adrian Mccoy

The stock of Novus Therapeutics, Inc. (NASDAQ:NVUS) hit a new 52-week high and has $7.28 target or 5.00 % above today’s $6.93 share price. The 7 months bullish chart indicates low risk for the $65.19M company. The 1-year high was reported on Jun, 4 by Barchart.com. If the $7.28 price target is reached, the company will be worth $3.26M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 10.12% or $0.78 during the last trading session, reaching $6.93. About 69,241 shares traded. Novus Therapeutics, Inc. (NASDAQ:NVUS) has risen 58.99% since June 4, 2017 and is uptrending. It has outperformed by 46.42% the S&P500.

Another recent and important Novus Therapeutics, Inc. (NASDAQ:NVUS) news was published by Benzinga.com which published an article titled: “30 Stocks Moving In Wednesday’s Mid-Day Session” on May 30, 2018.

Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. The company has market cap of $65.19 million. The Company’s lead product is a nasally-administered combination drug product intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. It currently has negative earnings. The firm also has a foam drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.